ClinicalTrials.gg
CompletedNCT03272165Updated Jun 9, 2022

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

A Phase 1 interventional study of MEDI1341 and Placebo in Parkinson's Disease, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
480th of 1,256
50 · median 36
Started
2017
with 84 others
Phase 1
175 of 1,649
32 open now
Registered
795th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 480th largest by enrollment of the 1,256 interventional ones that give a count, is one of 85 that started in 2017, is one of 175 in phase 1, and was the 795th registered.

Parkinson Disease

4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants.

Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks.

The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study of single ascending intravenous doses of MEDI1341 in male and nonfertile female healthy volunteers, aged 18 to 65 years.

The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Within each cohort, 6 participants will be randomized to receive MEDI1341 and 2 will be randomized to receive placebo. A Safety Review Committee will review data from each cohort before progression to the next higher dose cohort occurs. On Day 1, each randomized participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled safety, pharmacokinetic, pharmacodynamic, and immunogenicity assessments. Additional study assessments will occur on Days 2, 4, 8, 15, 22, 29, 43, 57, and 92.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Healthy Volunteers
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy, with no abnormality identified on the medical or laboratory evaluation at screening
  • Participants must weigh ≥50 kg and must have a between 18 and 32 kg/m\^2, inclusive
  • Participants must have a 12-lead recorded at screening that is normal for the appropriate age group and shows no abnormalities that will compromise safety in this study
  • Participants must have no clinically significant findings on the clinical neurological examinations at screening and at baseline or on the ophthalmic examination at screening.

Exclusion criteria

Exclusion Criteria:

  • Nicotine use within 6 months before screening
  • Considered to be at a high risk of developing a stroke
  • Significant medical history of dizziness, blackouts, fainting, or vaso-vagal attacks
  • History of any significant ophthalmic disorder, including congenital, genetic or acquired conditions affecting the retina or choroid
  • History of severe allergy or history of to immunizations or immunoglobulins
  • History of any significant psychiatric disorder
  • History of alcohol abuse
  • History of cancer within 5 years of screening
  • History of drug abuse
  • Any to Lumbar Puncture
  • Any abnormality in rhythm, conduction or morphology
  • Positive serologic findings at screening for (HIV) antibodies, surface antigen, or virus antibodies
  • Use of prescription or non-prescription drugs
  • For female participants, a positive serum or urine pregnancy test result at screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive a single intravenous (IV) infusion of placebo matched to MEDI1341 and will be followed up for 13 weeks.

    Drug: Placebo

  • Experimental
    Cohort 1: MEDI1341 Dose 1

    Participants will receive a single IV infusion of MEDI1341 Dose 1 and will be followed up for 13 weeks.

    Drug: MEDI1341

  • Experimental
    Cohort 2: MEDI1341 Dose 2

    Participants will receive a single IV infusion of MEDI1341 Dose 2 and will be followed up for 13 weeks.

    Drug: MEDI1341

  • Experimental
    Cohort 3: MEDI1341 Dose 3

    Participants will receive a single IV infusion of MEDI1341 Dose 3 and will be followed up for 13 weeks.

    Drug: MEDI1341

  • Experimental
    Cohort 4: MEDI1341 Dose 4

    Participants will receive a single IV infusion of MEDI1341 Dose 4 and will be followed up for 13 weeks.

    Drug: MEDI1341

  • Experimental
    Cohort 5: MEDI1341 Dose 5

    Participants will receive a single IV infusion of MEDI1341 Dose 5 and will be followed up for 13 weeks.

    Drug: MEDI1341

  • Experimental
    Cohort 6: MEDI1341 Dose 6

    Participants will receive a single IV infusion of MEDI1341 Dose 6 and will be followed up for 13 weeks.

    Drug: MEDI1341

Interventions

  • Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.

    Also known as: TAK-341

  • DrugPlacebo

    Participants will receive IV infusion of placebo matched to MEDI1341.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 92 days after a single dose of study drug

  2. Number of Participants With Abnormal Vital Signs, Physical and Neurological Examinations, and Body Weight Measurements Reported as TEAEs

    Vital signs assessment included body temperature, respiration rate, pulse rate, and blood pressure. Participants with abnormal vital signs, physical and neurological examinations, and body weight measurements reported as TEAEs are reported.

    Time frame: Day 1 through 92 days after a single dose of study drug

  3. Change from Baseline in 12-Lead Electrocardiogram (ECG) Data in Paper and Digital Recordings (PR Interval, QRS Duration, QT Interval, QTcF Interval, and RR Interval)

    Changes from baseline in 12-Lead ECG data in paper recordings (PR interval, QRS duration, QT interval, and QTcF interval) and digital recordings (PR interval, QRS duration, QT interval, QTcF interval, and RR interval) are reported.

    Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92

  4. Change from Baseline in Heart Rate by 12-Lead ECG in Paper and Digital Recordings

    Change from baseline in heart rate by 12-Lead ECG in paper and digital recordings are reported.

    Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92

  5. Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs

    Laboratory assessment included hematology, clinical chemistry, and urinalysis. Participants with abnormal laboratory parameters reported as TEAEs are reported.

    Time frame: Day 1 through 92 days after a single dose of study drug

  6. Number of Abnormal Findings for Ophthalmic Assessment (Ophthalmic Examination and Slit-lamp Examination) for Placebo and Cohorts 4 to 6 at Follow-up Visit

    Number of abnormal findings for ophthalmic assessment (ophthalmic examination and slit-lamp examination) at follow-up visit (Day 57) are reported.

    Time frame: Follow-up Visit (Day 57)

  7. Intraocular Pressure at Screening for Placebo and Cohorts 4 to 6

    Intraocular pressure at Screening (Day -49) is reported.

    Time frame: Screening (Day -49)

  8. Intraocular Pressure at Day 29 for Placebo and Cohorts 4 to 6

    Intraocular pressure at Day 29 is reported.

    Time frame: Day 29

  9. Intraocular Pressure at Day 92 for Placebo and Cohorts 4 to 6

    Intraocular pressure at Day 92 is reported.

    Time frame: Day 92

  10. Number of Participants With Injection Site Reactions

    Participants who had injection site reactions (bleeding, bruising, erythema, swelling, or induration) on Day 1 are reported.

    Time frame: Day 1

  11. Visual Analogue Scale (VAS) Pain Score for Site Reaction Pain

    The VAS (0 to 10 cm) was used to describe reaction site pain. The score 0 means 'no pain at all' and 10 score means 'worst pain imaginable'. The higher the VAS score, the greater the reaction site pain experienced.

    Time frame: Day 1 (within 24 hours after end of infusion)

  12. Number of Participants With Suicidal Ideation and Suicidal Behavior Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). * Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. * Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: preparatory acts or behaviour, aborted attempt, interrupted attempt, actual attempt (non-fatal), completed suicide.

    Time frame: Screening (Day -49) through 92 days after a single dose of study drug

  13. Number of Participants With Montreal Cognitive Assessment (MoCA) Total Score at Screening (Day -1)

    The MoCA is s standardized cognitive screening tool for mild cognitive impairment and dementia. The total score was used as outcome measure and this score ranges from 0-31, with higher scores representing better cognitive ability and scores below 26 were considered as cognitive dysfunction.

    Time frame: Screening (Day -1)

  14. Number of Participants With MoCA Total Score at Day 92

    The MoCA is s standardized cognitive screening tool for mild cognitive impairment and dementia. The total score was used as outcome measure and this score ranges from 0-31, with higher scores representing better cognitive ability and scores below 26 were considered as cognitive dysfunction.

    Time frame: Day 92

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of MEDI1341

    The Cmax of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  2. Time to Maximum Serum Concentration (tmax) of MEDI1341

    The tmax of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  3. Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of MEDI1341

    The AUC0-t of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  4. Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of MEDI1341

    The AUC0-∞ of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  5. Terminal Half-life (t1/2λz) of MEDI1341

    The t1/2λz of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  6. Serum Clearance (CL) of MEDI1341

    The CL of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  7. Volume of Distribution at Steady State (Vss) of MEDI1341

    The Vss of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  8. Mean Residence Time (MRT) of MEDI1341

    The MRT of MEDI1341 is reported.

    Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92

  9. Percentage Change From Baseline in Plasma Concentrations of Total α-synuclein

    Maximum change from baseline through Day 92 and change from baseline at Day 92 in plasma concentrations of total α-synuclein are reported.

    Time frame: Baseline (Day 1 predose) through Day 92

  10. Percentage Change From Baseline in Cerebrospinal Fluid Concentrations of Free α-synuclein

    Change from baseline in cerebrospinal fluid concentrations of free α-synuclein is reported.

    Time frame: Baseline (Day 1 predose) and Day 29

  11. Percentage of Participants With Positive Antidrug Antibodies (ADAs) to MEDI1341 by Titer Levels at Day 92

    Percentage of participants with positive ADAs to MEDI1341 by titer levels are reported.

    Time frame: Day 92

07

Study locations

2 sites
  • Research Site
    Dallas, Texas 75247, United States
  • Research Site
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsor tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Mar 2021, 41 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 41 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2017
First posted
Sep 5, 2017
StartActual
Oct 17, 2017
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03272165
Lead sponsor
AstraZeneca
Collaborators
Covance, MMS Holdings, Inc, Catalent, Takeda
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Oct 17, 2017
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Last update
Jun 9, 2022

Study contacts

Jeanelle Kam, MD, CPI
principal investigator · Covance Dallas CRU, USA
John E Blanchard, MD
principal investigator · Covance Madison CRU, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indenebart

Start the discussion